Date: July 16, 2024 By: Nick Kolev
On July 9, Ragon faculty member and Early Independence Fellow Charles Evavold, PhD, participated in a special seminar as part of the Science Seminar Series @RCCHU titled “Synthetic Biology Strategies for Human Health: From Yeasts to Immune Cells.”
Hosted by the Real Colegio Complutense at Harvard (RCCHU) and Harvard Medical School, this seminar explored innovative approaches to engineering living cells, using advanced techniques like CRISPR-Cas genomic editing.
Evavold highlighted the potential of engineered mRNA to reprogram cell death. Victor J. Cid, PhD, of the Complutense University of Madrid shared insights on humanized yeast models for genetic and pharmacological research. And Jon Kagan, PhD, of Boston Children’s Hospital and Harvard Medical School, discussed how re-wiring pathways in lymphoid cells can lead to new therapeutic designs. The event showcased the collaborative efforts of top researchers and institutions, emphasizing the transformative potential of synthetic biology in medical and pharmaceutical sciences.
The RCC is the sponsor of Dr. Cid for his sabbatical in the Evavold lab and sponsor for this special seminar.
Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have uncovered critical insights into how aging impairs the immune system’s ability to fight cancer.
This study, published in Immunity on August 30, used a non-human primate model to demonstrate that previous Mtb infection leads to a durable, protective immune response that is dependent on CD4+ T cells.
MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.